JANUVIA Drug Patent Profile

Which patents cover Januvia, and what generic alternatives are available?

Januvia is a drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this drug and four Paragraph IV challenges.

This drug has fifty-two patent family members in forty countries.

The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the sitagliptin phosphate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Januvia

A generic version of JANUVIA was approved as sitagliptin phosphate by WATSON LABS INC on December 30^th, 2025.

Summary for JANUVIA

International Patents:	52
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	161
Patent Applications:	6,035
Drug Prices:	Drug price information for JANUVIA
Drug Sales Revenues:	Drug sales revenues for JANUVIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JANUVIA
What excipients (inactive ingredients) are in JANUVIA?	JANUVIA excipients list
DailyMed Link:	JANUVIA at DailyMed

See drug prices for JANUVIA

See drug sales revenues for JANUVIA

Recent Clinical Trials for JANUVIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Polytechnic Institute, Mexico	Phase 4
Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social	Phase 4
Peking University People's Hospital	Phase 2

See all JANUVIA clinical trials

Pharmacology for JANUVIA

Drug Class	Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Paragraph IV (Patent) Challenges for JANUVIA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JANUVIA	Tablets	sitagliptin phosphate	50 mg/10 mg 50 mg/20 mg 50 mg/40 mg	021995	1	2012-11-06
JANUVIA	Tablets	sitagliptin phosphate	100 mg/20 mg	021995	1	2012-06-25
JANUVIA	Tablets	sitagliptin phosphate	100 mg/10 mg and 100 mg/40 mg	021995	1	2012-06-19
JANUVIA	Tablets	sitagliptin phosphate	25 mg, 50 mg and 100 mg	021995	6	2010-10-18

US Patents and Regulatory Information for JANUVIA

JANUVIA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-001	Oct 16, 2006	AB	RX	Yes	No					Y
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-002	Oct 16, 2006	AB	RX	Yes	No					Y
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	AB	RX	Yes	Yes					Y

Expired US Patents for JANUVIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-001	Oct 16, 2006
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-002	Oct 16, 2006

International Patents for JANUVIA

See the table below for patents covering JANUVIA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	202705
Australia	3023397
Australia	721477

Supplementary Protection Certificates for JANUVIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	PA2007006	Lithuania		PRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-EU/1/07/383/018 20070321
1412357	SPC/GB07/046	United Kingdom		PRODUCT NAME: SITAGLIPTIN PHOSPHATE MONOHYDRATE; REGISTERED: UK EU/1/07/383/001 20070323; UK EU/1/07/383/002 20070323; UK EU/1/07/383/003 20070323; UK EU/1/07/383/004 20070323; UK EU/1/07/383/005 20070323; UK EU/1/07/383/006 20070323; UK EU/1/07/383/007 20070323; UK EU/1/07/383/008 20070323; UK EU/1/07/383/009 20070323; UK EU/1/07/383/010 20070323; UK EU/1/07/383/011 20070323; UK EU/1/07/383/012 20070323; UK EU/1/07/383/013 20070323; UK EU/1/07/383/014 20070323; UK EU/1/07/383/015 20070323; UK EU/1/07/383/016 20070323; UK EU/1/07/383/017 20070323; UK EU/1/07/383/018 20070323
1412357	122007000056	Germany		PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE FUER SITAGLIPTINPHOSPHAT-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321

JANUVIA (sitagliptin) Market Dynamics and Financial Trajectory (2020-2025): US/Global Revenue Mix, Exclusivity-Driven Competition, and Investor-Relevant Risks

Last updated: June 19, 2026

JANUVIA (sitagliptin) has shifted from rapid growth into plateau as GLP-1 and SGLT2 competition intensified and as DPP-4 class demand normalized. Merck’s financial exposure has narrowed through loss of exclusivity on multiple dose strengths and broader access via authorized generics and generics, while continued brand endurance has depended on payer preference, formulary positioning, and lifecycle use in combination therapy.

---

JANUVIA sitagliptin revenue timeline: How have sales trended since exclusivity and generic entry?

What do the latest public filings show about JANUVIA’s commercial trajectory

Merck (NASDAQ: MRK) has reported sustained but declining JANUVIA revenue since the mid-cycle maturity phase of the DPP-4 class. The trajectory since 2020 has been characterized by:

• Continued decline versus prior peak years, with stability periods driven by account mix and substitution pace.
• Growing competitive pressure from incretin-based therapies (GLP-1 receptor agonists and dual agonists) and from SGLT2 inhibitors.
• Continued physician reliance on DPP-4 as a tolerable option in patients who cannot use injectables or are not ideal candidates for SGLT2 therapy.

Key market inflection points

• 2015-2018: Strong category adoption for DPP-4s; JANUVIA remains a core choice for type 2 diabetes (T2D).
• 2018-2020: Faster erosion as GLP-1 and SGLT2 offerings expanded and payer incentives strengthened.
• 2020-2025: Generic penetration continues; JANUVIA survives on brand preference in selected formularies and on combination therapy usage patterns.

Where revenue is most sensitive

JANUVIA revenue is most exposed to:

• US formulary dynamics: step-therapy rules, preferred drug lists, and payer rebates.
• Competition-driven switching: GLP-1 and SGLT2 “center-of-gravity” shift in guidelines and payer coverage.
• Patient mix: older patients and comorbidity profiles still support DPP-4 utilization, but slower growth follows increased preference for oral SGLT2 plus injectable GLP-1 strategies.

---

What market dynamics are driving JANUVIA growth or decline in type 2 diabetes?

DPP-4 category demand: Why has it matured

DPP-4 use has matured because:

• Mechanism efficacy and durability are viewed as incremental versus GLP-1 and SGLT2 for many outcomes-focused payers.
• Cardiovascular and renal outcome frameworks have pushed prescribers toward agents with demonstrated event reduction (SGLT2 and GLP-1 classes).
• Newer oral options and fixed-dose combination regimens reduce the relative share of standalone DPP-4 prescribing.

How payer incentives and formularies shape sitagliptin uptake

Payer dynamics typically reduce DPP-4 share when:

• Preferred lists add GLP-1 and SGLT2 due to negotiated rebate structures.
• Prior authorization is applied selectively for expensive incretin therapies, but net coverage still trends toward these agents when contracts stabilize.
• Generic price compression reduces brand economics but does not stop usage among clinicians who already treat stable patients.

US vs ex-US differences

JANUVIA’s non-US revenue tends to be:

• More variable by country reimbursement frameworks and generic launch pace.
• More sensitive to negotiated pricing controls and tendering systems where generic availability quickly shifts market share.

---

Which competitive pressures matter most for JANUVIA in 2020-2025?

GLP-1 and SGLT2: The dominant share-shifters

In T2D, the mainstream competitive set for JANUVIA includes:

• GLP-1 receptor agonists and dual agonists (injectable and increasingly oral formulations).
• SGLT2 inhibitors (oral; often used for cardiorenal benefits).

These classes have captured higher growth because:

• Guideline and payer coverage logic increasingly tie drug selection to outcomes beyond HbA1c.
• Market access strategies frequently steer higher-risk populations into SGLT2 and GLP-1 pathways.

DPP-4 class internal competition

Other DPP-4s that compete indirectly or directly include:

• Tradjenta (linagliptin)
• Onglyza (saxagliptin)
• Nesina (alogliptin) (varies by market)

The net effect: DPP-4s compete within class based on price, dosing convenience, and formulary placement, while the outside pressure comes from GLP-1/SGLT2.

---

When does JANUVIA lose exclusivity by strength, and how does that affect market share?

Generic access timeline: what investors should track

JANUVIA faced stepwise erosion tied to:

• Patent expiration for specific sitagliptin compositions and related protection layers.
• Launch of authorized generics and full generics across dose strengths.
• Continued substitution as pharmacy benefit managers (PBMs) update formulary and negotiate.

Market impact mechanics:

• The brand typically loses share first through tender and PBM switching.
• Remaining brand share can persist in “non-mandatory” segments (certain cash pay or Medicare Part D plan patterns) but trends toward generic substitution over time.

Dose-strength exposure

Investors should treat each strength as its own pocket of risk. For JANUVIA, the largest commercial erosion commonly maps to:

• The most widely prescribed strengths (commonly 100 mg in many markets).
• Strengths with earlier generic penetration and stronger PBM switching.

---

What is the Orange Book status of JANUVIA (sitagliptin) and how does it inform generic entry risk?

Orange Book framework investors use

Generic entry risk is driven by:

• Patent listings covering drug substance, drug product, and methods of use.
• Expiration timing and whether an ANDA triggers a Paragraph IV challenge.
• Data exclusivity or other exclusivity categories that can block approval timelines.

Investor signal: Paragraph IV activity and settlements

When Paragraph IV challenges occur, they often:

• Drive faster generic launches for affected strengths.
• Trigger settlement agreements that define launch “carve-outs” and entry dates.
• Influence residual brand pricing power.

(Details depend on specific Orange Book listings and per-strength patent families.)

---

What patent estate dynamics protect JANUVIA and what is the practical impact on competition?

Patent layers that historically mattered for sitagliptin

For oral small molecules, practical protection typically includes:

• Composition of matter protection around sitagliptin and salts (where applicable).
• Formulation patents (release, stability, polymorph, excipients).
• Method-of-use patents for T2D treatment regimens (less common for long-term block after core expiration).

How the estate changes competition behavior

Even when some later-life formulation or method patents exist, competition often accelerates because:

• The core commercial molecule loses the primary economic moat after substance expiration.
• PBMs and wholesalers optimize around generic cost, and the brand’s pricing leverage depends on residual IP rather than on additional incremental patents.

---

What generic entry risks exist for JANUVIA, and what launch scenarios are realistic?

Real-world “generic risk” drivers

• Residual patent gaps: if no blocking patents remain for a strength, ANDA approvals can land quickly post-expiration.
• Settlement-limited timing: if settlements delay launch, risk becomes a schedule-driven issue rather than an ongoing uncertainty.
• Authorized generic strategy: brand or license-holder may sell an AG that keeps price pressure while preserving brand distribution relationships.

Likely competitive outcome

• For a mature DPP-4 like JANUVIA, the dominant scenario is continued share loss to generics with periodic stability in brand share based on payer contracts and substitution friction.
• Any remaining IP tail typically reduces brand revenue more slowly than full generic substitution would, but does not recreate growth.

---

What FDA regulatory and labeling factors influence JANUVIA demand?

Label stability and clinical position

JANUVIA’s continued demand is supported by:

• A broadly established role in T2D management.
• Familiarity with long-term tolerability compared with some alternatives.
• Use cases in combination regimens where clinicians prefer oral DPP-4 options.

Supply chain and formulation availability

For mature oral solids:

• Generic availability does not usually cause supply instability that would lift brand demand.
• Tablet interchangeability with generics increases substitution speed if price incentives are aligned.

---

How does JANUVIA compare commercially with leading competitors in oral diabetes pharmacotherapy?

Comparison frame investors should use

Use these dimensions:

• Growth vs maturity
• Brand endurance vs generic exposure
• Payer preference trends and outcomes-driven prescribing

High-level competitive conclusion

• JANUVIA is a mature, price-pressured platform.
• GLP-1 and SGLT2 products have structural share advantage due to perceived outcomes and expanding line-of-therapy integration.

---

What settlements, litigation, and launch timing signals matter for JANUVIA’s financial trajectory?

Litigation-driven schedule changes

For established small molecules, litigation affects:

• Timing of ANDA approvals or launches.
• Scope of product copy differences (to avoid design-around in some situations).
• Whether the brand faces a “hard step-down” in revenue at an identified date.

Investor tracking metrics

• ANDA approval announcements mapped to Orange Book patents.
• Launch date evidence from pharmacy chain reporting and wholesaler buy patterns.
• PBM formulary changes that signal practical switch behavior.

---

How big is Merck’s financial exposure to JANUVIA versus newer franchises?

Business model shift

Merck has shifted focus toward:

• Oncology and immunology franchises for long-term growth.
• Newer metabolic and immunology pipeline investments to replace DPP-4 aging revenue.

Revenue relevance for capital allocation

For investors, the key point is that:

• JANUVIA becomes increasingly a cash-flow support rather than a growth driver.
• Merck’s strategic emphasis and R&D allocation increasingly reflect the need to protect and grow future therapeutic areas as JANUVIA faces ongoing price and share pressure.

---

Key Takeaways

• JANUVIA’s financial trajectory is dominated by maturity and generic substitution, not by new patient growth.
• GLP-1 and SGLT2 classes have structurally shifted payer preference and prescribing, limiting DPP-4 expansion.
• Exclusivity loss is a stepwise, strength-by-strength erosion pattern, typically translating into sharp share drops after generic launch windows.
• Litigation and settlement mechanics primarily change timing, while the economic endpoint is continued generic price compression.
• Merck’s broader financial resilience relies less on JANUVIA over time, with capital allocation increasingly driven by next-generation franchises.

---

FAQs

1. How do PBM formulary switches typically affect JANUVIA brand retention after generic entry?
2. Do DPP-4 competitors like linagliptin show similar revenue erosion patterns as sitagliptin?
3. What role do combination therapies play in slowing JANUVIA generic substitution in the US?
4. How does Medicare Part D coverage strategy influence JANUVIA demand versus GLP-1 and SGLT2 options?
5. What Orange Book patent families most commonly determine timing for ANDA launches for oral T2D products like sitagliptin?

---

References (APA)

1. Merck & Co., Inc. Annual Report on Form 10-K (latest available through 2025 filing cycle).
2. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (JANUVIA, sitagliptin listings).
3. FDA Label Information for JANUVIA (sitagliptin) tablets (most current label).

DrugChatter Q&A for JANUVIA

Generic januvia availability?
Is januvia a generic drug?
Januvia 100 mg tablet price?
Trade name januvia mexico?
Trade name januvia mexico trade name?